Literature DB >> 24786458

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.

Mitul D Gandhi1, Andrew M Evens, Timothy S Fenske, Paul Hamlin, Bertrand Coiffier, Andreas Engert, Alison J Moskowitz, Nilanjan Ghosh, Adam M Petrich, Jon Lomasney, Amy Chadburn, Gary S Wood, Katrin Salva, Beatrice Nardone, Steven M Trifilio, Dennis W Raisch, Dennis P West, Leo I Gordon, Jane N Winter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24786458      PMCID： PMC4007615          DOI： 10.1182/blood-2014-03-561878

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

Review 1.  Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment II.

Authors:  C R Taylor; R M Levenson
Journal:  Histopathology       Date:  2006-10       Impact factor: 5.087

2.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Authors:  Anas Younes; Nancy L Bartlett; John P Leonard; Dana A Kennedy; Carmel M Lynch; Eric L Sievers; Andres Forero-Torres
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

3.  U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

Authors:  R Angelo de Claro; Karen McGinn; Virginia Kwitkowski; Julie Bullock; Aakanksha Khandelwal; Bahru Habtemariam; Yanli Ouyang; Haleh Saber; Kyung Lee; Kallappa Koti; Mark Rothmann; Marjorie Shapiro; Francisco Borrego; Kathleen Clouse; Xiao Hong Chen; Janice Brown; Lara Akinsanya; Robert Kane; Edvardas Kaminskas; Ann Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2012-09-07       Impact factor: 12.531

Review 4.  Genetic risk factors for pancreatic disorders.

Authors:  David C Whitcomb
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

5.  Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Authors:  Barbara Pro; Ranjana Advani; Pauline Brice; Nancy L Bartlett; Joseph D Rosenblatt; Tim Illidge; Jeffrey Matous; Radhakrishnan Ramchandren; Michelle Fanale; Joseph M Connors; Yin Yang; Eric L Sievers; Dana A Kennedy; Andrei Shustov
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

6.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

7.  Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report.

Authors:  S A M Urru; E Mariotti; P Carta; S Massidda; M Marcias; R Murru; P Sanna; E Angelucci
Journal:  Drugs R D       Date:  2014-03
  7 in total
  16 in total

Review 1.  Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy.

Authors:  Alison J Moskowitz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.

Authors:  Lauren Shea; Neha Mehta-Shah
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

Review 3.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

4.  Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.

Authors:  Paul G Rubinstein; Page C Moore; Michelle A Rudek; David H Henry; Juan C Ramos; Lee Ratner; Erin Reid; Elad Sharon; Ariela Noy
Journal:  AIDS       Date:  2018-03-13       Impact factor: 4.177

Review 5.  Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.

Authors:  Solomon A Graf; Ajay K Gopal
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

Review 6.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

7.  Epigenetically Enhanced Photodynamic Therapy (ePDT) is Superior to Conventional Photodynamic Therapy for Inducing Apoptosis in Cutaneous T-Cell Lymphoma.

Authors:  Katrin Agnes Salva; Gary S Wood
Journal:  Photochem Photobiol       Date:  2015-10-12       Impact factor: 3.421

8.  ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma.

Authors:  Steven I Park; Thomas C Shea; Oludamilola Olajide; Nishitha M Reddy; Lihua E Budde; Nilanjan Ghosh; Allison M Deal; Jeanne F Noe; Stephen M Ansell
Journal:  Blood Adv       Date:  2020-06-09

Review 9.  Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.

Authors:  Helen Ma; Ahmed Sawas
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 10.  Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.

Authors:  Tanya Siddiqi; Sandra H Thomas; Robert Chen
Journal:  Pharmgenomics Pers Med       Date:  2014-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.